Research analysts covering BIOXYTRAN.
Recent press releases and 8-K filings for BIXT.
Bioxytran Announces Positive ProLectin-M Dose Optimization Results and Advances Toward Phase 3 Registrational Trial
BIXT
New Projects/Investments
- Bioxytran, Inc. announced positive dose optimization results for its lead antiviral candidate, ProLectin-M, confirming a 16,800 mg/day dosing regimen achieved 90% viral clearance by Day 5 in a 39-participant study.
- The company is initiating regulatory discussions with the U.S. FDA and India's CDSCO to finalize the design of a 408-participant Phase 3 registrational trial for ProLectin-M.
- The planned Phase 3 trial will be a randomized, placebo-controlled, outpatient study targeting standard-risk patients with mild-to-moderate COVID-19 and other viral infections, with a primary endpoint of viral clearance or clinical improvement by Day 5.
- Bioxytran is also evaluating its galectin antagonist platform for broader antiviral potential, including against H5N1 avian influenza, RSV, and H1N1 influenza, and advancing ProLectin-I for Long COVID.
Mar 4, 2026, 8:40 PM
Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M
BIXT
New Projects/Investments
- Bioxytran, Inc. announced positive Phase 1b/2a clinical study results for its antiviral drug, ProLectin-M, in patients with mild to moderate COVID-19.
- The study demonstrated that the highest dose of ProLectin-M (16,800 mg/day) achieved 90% viral clearance by Day 5, significantly outperforming the 20% observed in the placebo group (p=0.001).
- ProLectin-M also showed favorable safety and tolerability, with no serious adverse events or treatment-related discontinuations reported across all evaluated dose levels.
- These findings support continued clinical development of ProLectin-M as a potential oral therapeutic for viral infections.
Mar 2, 2026, 2:22 PM
Bioxytran Reports Positive Phase 1b/2a Results for ProLectin-M
BIXT
New Projects/Investments
- Bioxytran announced positive Phase 1b/2a trial results for its oral antiviral ProLectin-M in 39 hospitalized patients with mild to moderate COVID-19.
- At the highest dose (16,800 mg/day), 90% of patients achieved viral clearance and a two-point improvement on the WHO ordinal scale by Day 5, significantly outperforming the 20% in the placebo arm.
- The study observed no serious adverse events or treatment-related discontinuations, indicating a favorable tolerability profile for ProLectin-M.
- ProLectin-M, described as a novel galectin-targeting antiviral, is being advanced under an active U.S. Investigational New Drug (IND) framework, with these results supporting larger, well-controlled studies.
Mar 2, 2026, 2:17 PM
Bioxytran, Inc. Announces Commercial Distribution Agreement for A-SUQAR® Dietary Supplement
BIXT
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Bioxytran, Inc. entered into a commercial Distribution Agreement with Khoury Medical LTD on February 10, 2026, for the commercialization of A-SUQAR®, a chewable dietary supplement.
- This agreement signifies Bioxytran's transition from a development-stage organization to a company with recurring commercial revenue, while maintaining a capital-efficient commercial model.
- Khoury Medical will lead regulatory registration, marketing, and distribution of A-SUQAR®, which is designed to support healthy post-meal blood sugar levels, with manufacturing handled by Bioxytran's designated OEM.
- The agreement provides potential for volume-based marketplace exclusivity for Khoury Medical, subject to defined purchase thresholds and conditions.
- The agreement is structured to apply solely to non-pharmaceutical dietary products, preserving Bioxytran's ability to independently advance its pharmaceutical and antiviral programs.
Feb 17, 2026, 11:20 AM
Bioxytran Reports Positive Phase 2 Results for ProLectin-M
BIXT
New Projects/Investments
- Bioxytran, Inc. announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization trial evaluating ProLectin-M for acute viral infection.
- The trial demonstrated complete elimination of viral load in 100% of treated subjects by Day 7 (p = .001) and no viral rebounds during the 14-day post-treatment observation period.
- Based on these results, Bioxytran plans to advance regulatory discussions for late-stage clinical development and evaluate ProLectin-M across additional viral indications.
Feb 11, 2026, 11:04 AM
Bioxytran Reports Positive Phase 2 Results for ProLectin-M
BIXT
New Projects/Investments
- Bioxytran, Inc. announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization trial evaluating ProLectin-M in subjects with laboratory-confirmed acute viral infection.
- The trial demonstrated complete elimination of viral load in 100% of treated subjects by Day 7 compared to the placebo group (p=.001), with no viral rebounds observed during the 14-day post-treatment observation period.
- Bioxytran plans to advance regulatory discussions to support late-stage clinical development and evaluate ProLectin-M across additional viral indications, consistent with its broad-spectrum antiviral profile.
Feb 11, 2026, 11:00 AM
BioXyTran Presents Promising Antiviral Phase 2 Results and Stroke Treatment Development
BIXT
Product Launch
New Projects/Investments
Guidance Update
- BioXyTran (BIXT) is developing a broad-range antiviral drug that blocks galectin receptors on viruses. A Phase 2 clinical trial for COVID-19 demonstrated 88% of patients had no detectable virus by day 3 and 100% by day 7, with no adverse effects.
- A second Phase 2 study for dose response of the antiviral is currently being analyzed, with results expected soon. The company aims to commercialize the antiviral as a nutraceutical while pursuing Phase 3 trials with a partner for specific medical claims.
- The company is also developing BXT-25, a universal oxygen carrier for early stroke treatment, which is 5,000 times smaller than red blood cells and stable for years at room temperature. Toxicity testing is nearing completion, and clinical trials will commence once funding is available.
- BioXyTran was formed in 2017, has 37 million shares in float, and is currently valued between $5 and $7. The estimated total antiviral market is approximately $80 billion.
Feb 5, 2026, 3:30 PM
BioXyTran provides updates on broad-range antiviral and oxygen carrier development
BIXT
New Projects/Investments
Revenue Acceleration/Inflection
- BioXyTran (BIXT) has completed a Phase 2 double-blind placebo-controlled clinical trial for a broad-range antiviral drug, demonstrating that 88% of COVID-19 patients had no detected virus by day 3 and 100% by day 7.
- A second confirmatory Phase 2 trial for the antiviral, which also evaluates dose response, is currently being analyzed, with data expected "very soon".
- The company is also developing BXT-25, a universal oxygen carrier for early stroke treatment, which is entering clinical trials after toxicity testing.
- BIXT was formed in 2017, has 37 million shares in the float, and is currently valued between 5 and 7.
Feb 5, 2026, 3:30 PM
Bioxytran Updates on Antiviral Drug Development and Oxygen Carrier Progress
BIXT
New Projects/Investments
Product Launch
- Bioxytran (BIXT) is developing a broad-range antiviral drug that targets galectin receptors on viruses, effective against COVID-19, influenza, shingles, long COVID, conjunctivitis, and RSV.
- A double-blind placebo-controlled Phase II clinical trial for COVID-19 demonstrated 88% of patients had no detected virus by day three and no detection by day seven, significantly faster than Paxlovid's reported efficacy.
- A second confirmatory Phase II trial for dose response is currently undergoing data analysis, with results anticipated soon. The company plans to pursue Phase III trials for a medical claim, potentially through partnerships, targeting an estimated $80 billion antiviral market.
- Bioxytran is also advancing BXT-25, a universal oxygen carrier derived from camel hemoglobin, for early stroke treatment, which is entering clinical trials.
Feb 5, 2026, 3:30 PM
Bioxytran Provides Update on Clinical Programs and Partnership Strategy
BIXT
New Projects/Investments
Guidance Update
- Bioxytran (BIXT), a clinical-stage biotech, is developing three platform technologies: broad-spectrum antivirals, an oxygenation molecule for stroke treatment, and a cancer metastasis drug.
- Its broad-spectrum oral antiviral, ProLectin-M, recently completed clinical trials, demonstrating 100% viral reduction in seven days, with a top-line data readout expected before year-end 2025.
- The company is actively seeking a collaboration partner for its antiviral for an FDA trial and plans to present its cancer metastasis platform at the upcoming J.P. Morgan Conference to explore partnerships for boosting immunotherapy response rates.
- Bioxytran's oxygenation molecule for stroke is designed to provide an "oxygen bridge" to reduce brain damage, targeting a market potentially larger than the existing $6 billion-$7 billion annual tPA market.
Dec 11, 2025, 7:55 PM
Fintool News
In-depth analysis and coverage of BIOXYTRAN.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more